With Heterocyclic Compound Patents (Class 514/161)
-
Publication number: 20130064891Abstract: The present invention relates a pharmaceutical composition comprising esomeprazole magnesium dihydrate, non-steroidal anti-inflammatory drug and one or more pharmaceutically acceptable excipients, wherein non-steroidal anti-inflammatory drug is present in two or more portions. More particularly, the invention relates to compositions comprising Esomeprazole and Naproxen and a process for preparation thereof. Further invention relates to a pharmaceutical composition comprising esomeprazole magnesium dihydrate, non-steroidal anti-inflammatory drug and one or more pharmaceutically acceptable excipients wherein, esomeprazole magnesium dihydrate and non-steroidal anti-inflammatory drug provides co-ordinated release.Type: ApplicationFiled: May 20, 2011Publication date: March 14, 2013Inventors: Ashok Sahoo, Ashish Guha, Shrenik Kole, Makrand Avachat
-
Publication number: 20130065818Abstract: The present invention discloses ophthalmic and otic compositions of facially amphiphilic antimicrobial polymers and oligomers and their uses, including their use in methods for treating and preventing ophthalmic infections and otic infections in humans and animals.Type: ApplicationFiled: October 26, 2012Publication date: March 14, 2013Applicant: POLYMEDIXInventor: PolyMedix
-
Publication number: 20130045173Abstract: The present invention provides a compound having an excellent inhibitory action on melanin production and being useful as a whitening agent, and a skin external preparation containing the compound. The whitening agent of the present invention comprises, as an active ingredient, a compound represented by formula (1) or a pharmacologically acceptable salt thereof: wherein, R1, R3, R4, and R6 are each independently C1-3 alkyl; and R2 and R5 are each independently a hydrogen atom or C1-3 alkyl.Type: ApplicationFiled: October 22, 2012Publication date: February 21, 2013Applicant: SHISEDIO COMPANY LTD.Inventor: SHISEDIO COMPANY LTD.
-
Patent number: 8372823Abstract: Certain tetracyclic compounds are described, which may be used in pharmaceutical compositions and methods for treating disease states, disorders, and conditions mediated by fatty acid amide hydrolase (FAAH) activity. Thus, the compounds may be administered to treat, e.g., anxiety, pain, inflammation, sleep disorders, eating disorders, or movement disorders (such as multiple sclerosis).Type: GrantFiled: May 23, 2008Date of Patent: February 12, 2013Assignee: The Scripps Research InstituteInventor: Dale L. Boger
-
Publication number: 20130035316Abstract: This invention relates to the oral pharmaceutical composition of metformin and rosuvastatin. In detail, this invention comprising metformin, rosuvastatin, sustained release carriers and/or excipients reduces the side effects caused by statins and enhances safety, patients' convenience and compliance with its one-per-day dosage. In addition, regulation of an early effective blood concentration of the drug and maintenance of the drug's concentration at a steady level in vivo by a controlled-release can be advantageously used as a pharmaceutical composition for preventing and treating hyperlipidemia.Type: ApplicationFiled: December 30, 2010Publication date: February 7, 2013Applicant: BCWORLD PHARM. CO., LTD.Inventors: Hearan Suh, Myungkwan Chun, Taekun An, Juhuen Choi, Hyunmi Seo, Jisung Lim, Choongho Ryu, Jeong Ku, Youngdai Seo, Younji Shin, Junhee Lee
-
Publication number: 20130028938Abstract: The present invention relates to a solid pharmaceutical dosage form comprising ticagrelor as pharmaceutically active ingredient, to certain particles of ticagrelor and to processes of preparing the same.Type: ApplicationFiled: December 20, 2010Publication date: January 31, 2013Applicant: ratiopharm GmbHInventors: Sandra Brueck, Dominique Meergans
-
Patent number: 8361499Abstract: A solid oral controlled-release dosage form of hydrocodone is disclosed, the dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof, and controlled release material.Type: GrantFiled: June 28, 2012Date of Patent: January 29, 2013Assignee: Purdue Pharma L.P.Inventors: Benjamin Oshlack, Hua-Pin Huang, John K. Masselink, Alfred P. Tonelli
-
Publication number: 20130023500Abstract: A composition comprising a substantially purified compound of the formula: in combination with at least one additional therapeutic agent, and methods of preventing or treating cancer and a condition treatable by the inhibition of vacuolar-type (H+)-ATPase.Type: ApplicationFiled: October 1, 2012Publication date: January 24, 2013Applicants: Human ServicesInventor: The United States of America, as represented by the Secretary, Department of Health and Human Services
-
Patent number: 8357674Abstract: This invention relates to novel compounds which are derivatives of the phosphodiesterase inhibitor, cilostazol and pharmaceutically acceptable salts thereof. This invention also provides pyrogen-free compositions comprising one or more compounds of the invention and the use of the disclosed compounds and compositions in methods of treating diseases and conditions that are treated by administration of an phosphodiesterase inhibitor, such as cilostazol. The invention also relates to the use of the disclosed compounds and compositions as reagents in analytical studies involving cilostazol.Type: GrantFiled: June 29, 2012Date of Patent: January 22, 2013Assignee: CoNCERT Pharmaceuticals, Inc.Inventors: Julie F. Liu, Rose A. Persichetti
-
Publication number: 20130018020Abstract: The present invention relates to a melanin production inhibitor containing, as active ingredients, tranexamic acid and nicotinic acid amide, which inhibits the formation of skin melanocytes, and to a cosmetic composition which contains the melanin production inhibitor as an active ingredient and has the effects of reducing liver spots, blemishes, freckles and post-inflammatory hyperpigmentation, improving skin tone and texture and whitening the skin.Type: ApplicationFiled: March 30, 2011Publication date: January 17, 2013Applicant: AMOREPACIFIC CORPORATIONInventors: Hong Ju Shin, Do Hoon Kim, Jeong Hwan Kim, Hyun Ju Koh, Won Seok Park
-
Patent number: 8349817Abstract: This invention relates to novel compounds which are derivatives of the phosphodiesterase inhibitor, cilostazol and pharmaceutically acceptable salts thereof. This invention also provides pyrogen-free compositions comprising one or more compounds of the invention and the use of the disclosed compounds and compositions in methods of treating diseases and conditions that are treated by administration of a phosphodiesterase inhibitor, such as cilostazol. The invention also relates to the use of the disclosed compounds and compositions as reagents in analytical studies involving cilostazol.Type: GrantFiled: December 22, 2009Date of Patent: January 8, 2013Assignee: CoNCERT Pharmaceuticals, Inc.Inventors: Rose A. Persichetti, Julie F. Liu, Craig E. Masse, Scott L. Harbeson
-
Publication number: 20120328674Abstract: The present invention relates generally to methods and compositions for prophylaxis and treatment of skin conditions. Topical compositions which protect the skin from UV radiation damage and treat UV radiation damage done to the skin are provided according to embodiments of the present invention which include at least one cyanin derived from a plant and at least one additional agent selected from the group consisting of: a UV radiation reflector, a UV screening agent, niacinamide, and a combination of two or more thereof.Type: ApplicationFiled: March 2, 2011Publication date: December 27, 2012Inventors: Roy J. Mankovitz, Kathleen Barry Mankovitz
-
Publication number: 20120329763Abstract: New compounds, namely, (7aS,2?S)-2-oxoclopidogrel and its pharmaceutically acceptable salts thereof are disclosed for treatment or prophylaxis of thrombo-embolism and/or cardiovascular diseases.Type: ApplicationFiled: March 23, 2012Publication date: December 27, 2012Inventors: Ashok KUMAR, Satish Rajanikant SOUDAGAR, Nellithanath Thankachen BYJU, Gaurav SAHAL, Arpana Prashant MATHUR, Sanjay Pandurang GAWADE, Dinesh Kanji BHADRA, Devki MOJE
-
Publication number: 20120329762Abstract: New compounds, namely, (7aS,2?S)-2-oxoclopidogrel and its pharmaceutically acceptable salts thereof are disclosed for treatment or prophylaxis of thrombo-embolism and/or cardiovascular diseases.Type: ApplicationFiled: January 6, 2012Publication date: December 27, 2012Inventors: Ashok Kumar, Satish Rajanikant Soudagar, Nellithanath Thankachen Byju, Gaurav Sahal, Arpana Prashant Mathur, Sanjay Pandurang Gawade, Dinesh Kanji Bhadra, Devki Moje
-
Publication number: 20120322772Abstract: The present application relates to novel dipyridyl-dihydropyrazolones, processes for their preparation, their use for treatment and/or prophylaxis of diseases and their use for the preparation of medicaments for treatment and/or prophylaxis of diseases, in particular cardiovascular and hematological diseases and kidney diseases, and for promoting wound healing.Type: ApplicationFiled: August 24, 2012Publication date: December 20, 2012Applicant: Bayer Intellectual Property GmbHInventors: Ingo FLAMME, Jens-Kerim ERGÜDEN, Felix OEHME, Kai THEDE, Gunter KARIG, Alexander KUHL, Hanno WILD, Joachim SCHUHMACHER, Peter KOLKHOF, Lars BÄRFACKER, Joachim HÜTTER
-
Publication number: 20120316140Abstract: A soluble aspirin composition, comprising: (i) granules including aspirin, heat-treated bicarbonate salt, pharmaceutically-acceptable resin and surfactant, in mixture with: (ii) crystalline particles of pharmaceutically-acceptable acid; and (iii) crystalline particles of heat-treated bicarbonate salt; wherein the soluble aspirin composition when introduced to water undergoes reaction of the crystalline particles of pharmaceutically-acceptable acid with the heat-treated bicarbonate salt and the aspirin to effect effervescing action and disintegration of the granules with conversion of the aspirin to an acetylsalicylate compound of the bicarbonate salt cation so that the composition rapidly dissolves in the water without occurrence of undissolved residue. The composition is solublizable within 30 seconds in cool to cold water to provide an effervescent analgesic solution that can be readily orally administered to an individual in need of analgesia.Type: ApplicationFiled: June 13, 2011Publication date: December 13, 2012Applicant: PHARMSTAR PHARMACEUTICALS, INC.Inventor: Howard Phykitt
-
Publication number: 20120301549Abstract: Provided is a complex formulation for the prevention or treatment of cardiovascular diseases, comprising: a) aspirin coated with a barrier containing a hydrophobic additive; and b) an HMG-CoA reductase inhibitor, which has improved storage stability by preventing the deterioration in the stability of HMG-CoA reductase which is caused by salicylic acid, thereby being used in the treatment of hypertension and hypercholesterolemia.Type: ApplicationFiled: January 26, 2011Publication date: November 29, 2012Applicant: HANMI SCIENCE CO., LTD.Inventors: Jong Soo Woo, Jae Hyun Park, Yong Il Kim, Young Jun Na, Jun Young Choi, Yun Ah Lee
-
Patent number: 8318707Abstract: The present invention relates to the use of 6-(benzyl-amino)-2(S)-[[1-(hydroxymethyl) propyl]amino]-9-isopropylpurine) or at least one of its pharmaceutical acceptable salts for manufacturing a medication intended for the prevention and/or treatment of neurological diseases, in particular associated with neurological lesions.Type: GrantFiled: March 30, 2007Date of Patent: November 27, 2012Assignee: NeurokinInventors: Serge Timsit, Bénédicte Menn, Laurent Meijer
-
Publication number: 20120294943Abstract: Methods and compositions for reducing the frequency of urination are disclosed. One method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising an analgesic agent formulated in an extended-release formulation. Another method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising multiple active ingredients formulated for extended-release. Yet another method comprises administering to a subject in need thereof an effective amount of a diuretic followed with another administration of a pharmaceutical composition comprising an analgesic agent formulated for extended-release.Type: ApplicationFiled: July 27, 2012Publication date: November 22, 2012Applicant: Wellesley Pharmaceuticals, LLCInventor: David A. DILL
-
Publication number: 20120283226Abstract: A dermatological or cosmetic composition for skin care which includes the salt of an ?-hydroxy acid, ?-hydroxy acid, poly hydroxy acid or bionic acid in combination with niacinamide.Type: ApplicationFiled: August 31, 2010Publication date: November 8, 2012Applicant: RECKITT BENCKISER HEALTHCARE INTERNATIONAL LIMITEDInventors: Carolyn Buckley, Stuart Jackson, Tony Rawlings
-
Publication number: 20120282223Abstract: The invention relates to a stable amorphous form of (5-Fluoro-2-methyl-3-quinolin-2-ylmethyl-indol-1-yl)-acetic acid and its use in the treatment of conditions mediated by the action of PGD2 at the CRTH2 receptor.Type: ApplicationFiled: March 7, 2012Publication date: November 8, 2012Inventors: Aimesther BETANCOURT, Marc LEMIEUX, Roch THIBERT
-
Publication number: 20120264704Abstract: The present application relates to novel substituted dihydropyrazolone derivatives, processes for their preparation, their use for treatment and/or prophylaxis of diseases and their use for the preparation of medicaments for treatment and/or prophylaxis of diseases, in particular cardiovascular and hematological diseases and kidney diseases, and for promoting wound healing.Type: ApplicationFiled: October 26, 2007Publication date: October 18, 2012Inventors: Kai Thede, Ingo Flamme, Felix Oehme, Jens-Kerim Ergüden, Friederike Stoll, Joachim Schuhmacher, Hanno Wild, Peter Kolkhof, Hartmut Beck, Metin Akbaba, Mario Jeske
-
Publication number: 20120264721Abstract: This invention relates to novel compounds which are derivatives of the phosphodiesterase inhibitor, cilostazol and pharmaceutically acceptable salts thereof. This invention also provides pyrogen-free compositions comprising one or more compounds of the invention and the use of the disclosed compounds and compositions in methods of treating diseases and conditions that are treated by administration of an phosphodiesterase inhibitor, such as cilostazol. The invention also relates to the use of the disclosed compounds and compositions as reagents in analytical studies involving cilostazol.Type: ApplicationFiled: June 29, 2012Publication date: October 18, 2012Applicant: CONCERT PHARMACEUTICALS, INC.Inventors: Julie F. Liu, Rose A. Persichetti
-
Publication number: 20120252766Abstract: The invention relates to a new co-crystal of 4-{[(6-chloropyrid-3-yl)methyl](2,2-difluoroethyl)amino}furan-2(5H)-one (I) with salicylic acid, and also to processes for preparation thereof and use thereof.Type: ApplicationFiled: October 26, 2010Publication date: October 4, 2012Applicant: BAYER ITECHNOLOGY SERVICES GMBHInventors: Martin Weiss, Dirk Storch, Wolfgang Wirth, Britta Olenik, Hans-Christoph Weiss, Ulrich Schwiedop
-
Publication number: 20120252765Abstract: Use of irbesartan or one of its pharmaceutically acceptable salts for the preparation of a medicament for the prevention of hospitalization for heart failure.Type: ApplicationFiled: February 27, 2012Publication date: October 4, 2012Applicant: SANOFIInventors: Catherine MARCHESE, Christophe GAUDIN
-
Publication number: 20120244221Abstract: Methods and compositions for reducing the frequency of urination are disclosed. One method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising an analgesic agent formulated in an extended-release formulation. Another method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising multiple active ingredients formulated for extended-release. Yet another method comprises administering to a subject in need thereof an effective amount of a diuretic followed with another administration of a pharmaceutical composition comprising an analgesic agent formulated for extended-release.Type: ApplicationFiled: June 4, 2012Publication date: September 27, 2012Applicant: WELLESLEY PHARMACEUTICALS, LLCInventor: David A. Dill
-
Publication number: 20120237595Abstract: Methods of treating, preventing and/or managing cancer as well as and diseases and disorders associated with, or characterized by, undesired angiogenesis are disclosed. Specific methods encompass the administration of an immunomodulatory compound alone or in combination with a second active ingredient. The invention further relates to methods of reducing or avoiding adverse side effects associated with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy which comprise the administration of an immunomodulatory compound. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed.Type: ApplicationFiled: May 30, 2012Publication date: September 20, 2012Inventor: Jerome B. Zeldis
-
Publication number: 20120230984Abstract: The present invention provides methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds, as well as methods of treating, preventing or ameliorating symptoms associated with such diseases. Specific examples of autoimmune diseases that can be treated or prevented with the compounds include rheumatoid arthritis and/or its associated symptoms, systemic lups erythematosis and/or its associated symptoms and multiple sclerosis and/or its associated symptoms.Type: ApplicationFiled: March 13, 2012Publication date: September 13, 2012Applicant: RIGEL PHARMACEUTICALS, INC.Inventors: Rajinder Singh, Ankush Argade, Donald G. Payan, Jeffrey Clough, Holger Keim, Somasekhar Bhamidipati, Catherine Sylvain, Hui Li
-
Publication number: 20120232041Abstract: The present invention provides a pharmaceutical composition for the treatment and prophylaxis of angina and myocardial infarction, wherein a combination of a tea extract (catechins) and an antianginal drug are proved therapeutically potent in treating angina and mycocardial infarction induced from myocardial ischemia. The present invention also provides a use of a tea extract (catechins) in treating and preventing angina.Type: ApplicationFiled: July 10, 2009Publication date: September 13, 2012Applicant: SINPHAR TIAN-LIPHARMACEUTICAL CO., LTD. (HANGZHOU)Inventors: Muh-Hwan Su, Jing Jing Justine Tang, Hang-Ching Lin
-
Publication number: 20120201816Abstract: The present application describes lactam-containing compounds and derivatives thereof of Formula I: P4—P-M-M4??I or pharmaceutically acceptable salt forms thereof, wherein ring P, if present is a 5-7 membered carbocycle or heterocycle and ring M is a 5-7 membered carbocycle or heterocycle. Compounds of the present invention are useful as inhibitors of trypsin-like serine proteases, specifically factor Xa.Type: ApplicationFiled: April 12, 2012Publication date: August 9, 2012Applicant: BRISTOL-MYERS SQUIBB COMPANYInventors: Donald J. P. Pinto, Mimi L. Quan, Michael J. Orwat, Yun-Long Li, Wei Han, Jennifer X. Qiao, Patrick Y. S. Lam, Stephanie L. Koch
-
Patent number: 8231898Abstract: A solid oral controlled-release dosage form of hydrocodone is disclosed, the dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof, and controlled release material.Type: GrantFiled: October 28, 2010Date of Patent: July 31, 2012Assignee: Purdue Pharma L.P.Inventors: Benjamin Oshlack, Hua-Pin Huang, John K. Masselink, Alfred P. Tonelli
-
Publication number: 20120189684Abstract: This invention relates to skincare compositions, in particular compositions effective in the treatment of acne vulgaris, and to methods of treatment of the skin that involve the application of such compositions, wherein the compositions comprise salicylic acid or a salt thereof in combination with at 2 actives selected from the group consisting of lactic acid or a salt thereof; glycyrrhizinic acid or a salt or derivative thereof; bisabolol; cetylhydroxyproline palmitamide; allantoin; niacinamide; and epilobium angustifolium extract.Type: ApplicationFiled: July 19, 2010Publication date: July 26, 2012Applicant: Reckitt Benckiser Healthcare International LimitedInventors: Carolyn Buckley, Stuart Jackson, Neil Kilcullen, Diane Marie Pavis
-
Publication number: 20120183600Abstract: The invention relates to a composition that includes a first agent selected from the group consisting of an oxidative phosphorylation inhibitor, an ionophore, and an adenosine 5?-monophosphate-activated protein kinase (AMPK) activator; a second agent that possesses anti-inflammatory activity; and a third agent that possesses serotonin activity.Type: ApplicationFiled: January 4, 2012Publication date: July 19, 2012Inventor: Chien-Hung Chen
-
Publication number: 20120178724Abstract: In accordance with the present invention, novel methods and formulations are provided for treating and preventing the incidence of drug-induced pro-arrhythmia, including torsades de pointes. The methods and formulations comprise a combination of a drug that induces torsade de pointes, such as Class III antiarrhythmics, certain antimicrobials, antihistamines, antidepressants, antipsychotics, diuretics, with an aspirin and/or a statin. In certain embodiments, the compositions and methods for treatment comprise azimilide and aspirin and/or a statin. These compositions may be administered by different routes, including orally. In certain embodiments where the antiarrhythmic is azimilide it may be administered orally in a dose of about 25 mg to about 300 mg.Type: ApplicationFiled: March 22, 2012Publication date: July 12, 2012Applicant: WARNER CHILCOTT COMPANY, LLCInventors: Joseph Michael Sprafka, II, Jose Mauro Goulart-Brum
-
Publication number: 20120177736Abstract: The present disclosure is directed to a method for treating a disease or disorder in a patient at risk of developing an NSAID-associated ulcer by administering to the patient in need thereof a pharmaceutical composition in unit dosage form comprising aspirin, or a pharmaceutically acceptable salt thereof, and an acid inhibitor to the at risk patient and thereby decreasing the patient's risk of developing an ulcer.Type: ApplicationFiled: January 6, 2012Publication date: July 12, 2012Applicant: POZEN INC.Inventor: JOHN R. PLACHETKA
-
Publication number: 20120172329Abstract: A composition (e.g., a phytochemical composition) including a predetermined concentration of xanthones, and in certain embodiments predetermined concentrations of both xanthones and sesamin. The composition facilitates at least one of decreasing pro-inflammatory cytokines, increasing anti-inflammatory cytokines, enhancing a connective tissue anti- degeneration effect, and inhibiting viral neuraminidase (e.g. neuraminidase of an influenza A virus). The composition can further decrease at least one of gene expression and release of pro-inflammatory cytokines. The phytochemical composition can increase at least one of gene expression and release of anti-inflammatory cytokines. The phytochemical composition provides at least one of an anti-inflammatory, an anti-viral (e.g., anti-influenza), and a connective tissue anti-degradation effect in a living organism. A use of xanthones for manufacturing phytochemical compositions that include predetermined concentrations of xanthones is also provided.Type: ApplicationFiled: September 14, 2009Publication date: July 5, 2012Applicant: Thailand Excellence Center for Tissue EngineeringInventor: Prachya Kongtawelert
-
Patent number: 8211876Abstract: Inflammatory bowel diseases are represented by two idiopathic disorders, which include ulcerative colitis and Crohn's disease. Ulcerative colitis is restricted to the colon and involves uncertain and inflammation of the lining (mucosa) of the large intestine. Crohn's disease, on the other hand, can involve the mucosa of the small and/or large intestine and may involve deeper layers of the bowel wall. The present invention is a combination of 5-aminosalicylic acid and one or more antioxidants (e.g., N-acetylcysteine) for treating such inflammatory bowel diseases.Type: GrantFiled: December 24, 2009Date of Patent: July 3, 2012Assignee: The Regents of the University of OklahomaInventor: Richard F. Harty
-
Publication number: 20120164193Abstract: Methods and compositions for reducing the frequency of urination are disclosed. One method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising an analgesic agent formulated in an extended-release formulation. Another method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising multiple active ingredients formulated for extended-release. Yet another method comprises administering to a subject in need thereof an effective amount of a diuretic followed with another administration of an pharmaceutical composition comprising an analgesic agent formulated for extended-release.Type: ApplicationFiled: March 19, 2012Publication date: June 28, 2012Applicant: WELLESLEY PHARMACEUTICALS, LLCInventor: David A. Dill
-
Publication number: 20120164139Abstract: Provided herein are methods of treating gastrointestinal motility disorders by targeting the dopamine 3 receptor (D3R). A D3R agonist is administered to a subject to decrease gastrointestinal motility to treat the disorder. A D3R antagonist is administered to a subject to decrease gastrointestinal motility to treat the disorder.Type: ApplicationFiled: March 6, 2012Publication date: June 28, 2012Applicant: The Board of Regents of the University of Texas SystemInventors: Pankaj Jay Pasricha, Maria-Adelaide Micci
-
Publication number: 20120164192Abstract: Methods and compositions for reducing the frequency of urination are disclosed. One method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising an analgesic agent formulated in a delayed-release formulation. Another method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising multiple active ingredients. Yet another method comprises administering to a subject in need thereof an effective amount of a diuretic followed with another administration of an pharmaceutical composition comprising an analgesic agent.Type: ApplicationFiled: March 19, 2012Publication date: June 28, 2012Applicant: WELLESLEY PHARMACEUTICALS, LLCInventor: David A. Dill
-
Publication number: 20120157403Abstract: Heterocyclic-substituted tricyclics of the formula or a pharmaceutically acceptable salt or solvate of said compound, isomer or racemic mixture wherein represents an optional double bond, the dotted line is optionally a bond or no bond, resulting in a double bond or a single bond, as permitted by the valency requirement and wherein E, A, G M, Het, B, X, R3, R10, R11, R32 and R33 are herein defined and the remaining substituents are as defined in the specification, are disclosed, as well as pharmaceutical compositions containing them and a method of treating diseases associated with thrombosis, atherosclerosis, restenosis, hypertension, angina pectoris, arrhythmia, heart failure, and cancer by administering said compounds. Combination therapy with other cardiovascular agents is also claimed.Type: ApplicationFiled: February 24, 2012Publication date: June 21, 2012Inventors: Samuel Chackalamannil, Mariappan V. Chelliah, Yuguang Wang, Yan Xia
-
Publication number: 20120157415Abstract: There is provided a hemihydrate form of the sodium salt of pemirolast.Type: ApplicationFiled: June 15, 2010Publication date: June 21, 2012Applicant: CARDOZ ABInventors: Anett Perlberg, Martin Viertelhaus, Ulrika Rosentrôm, Karol Horvath
-
Publication number: 20120141554Abstract: Methods and compositions for reducing the frequency of urination are disclosed. One method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising an analgesic agent formulated in a delayed-release formulation. Another method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising multiple active ingredients. Yet another method comprises administering to a subject in need thereof an effective amount of a diuretic followed with another administration of an pharmaceutical composition comprising an analgesic agent.Type: ApplicationFiled: January 4, 2012Publication date: June 7, 2012Applicant: WELLESLEY PHARMACEUTICALS, LLCInventor: David A. Dill
-
Publication number: 20120141467Abstract: Provided herein is a method for treating a tracheo-bronchial-alveolar tract disease in a subject in need thereof, the method comprising the step of administering to a subject in need of such treatment a pharmaceutical composition comprising a therapeutically effective amount of ascorbate or a derivative thereof. Also provided is a method for treating non-Hodgkin's lymphoma in a subject in need thereof, the method comprising the step of administering to the subject in need of such treatment a pharmaceutical composition comprising a therapeutically effective amount of ascorbate or a derivative thereof.Type: ApplicationFiled: December 3, 2010Publication date: June 7, 2012Inventor: Daniel J. Schneider
-
Publication number: 20120135050Abstract: Methods and compositions for reducing the frequency of urination are disclosed. One method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising an analgesic agent formulated in an extended-release formulation. Another method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising multiple active ingredients formulated for extended-release. Yet another method comprises administering to a subject in need thereof an effective amount of a diuretic followed with another administration of an pharmaceutical composition comprising an analgesic agent formulated for extended-release.Type: ApplicationFiled: January 4, 2012Publication date: May 31, 2012Applicant: WELLESLEY PHARMACEUTICALS, LLCInventor: David A. DILL
-
Publication number: 20120128654Abstract: Methods for inhibiting the progression of neurodegenerative diseases and treating neurotrauma-induced damage and cerebrovascular disease are provided herein, the methods including the administration of a safe and effective amount of allantoin to a patient in need thereof. Also provided are pharmaceutical compositions including allantoin for the inhibition of the progression of neurodegenerative diseases and for the treatment of neurotrauma-induced damage and cerebrovascular disease.Type: ApplicationFiled: April 23, 2010Publication date: May 24, 2012Applicant: UNIVERSITY OF CINCINNATIInventors: Brian T. Terpstra, Caryl E. Sortwell
-
Publication number: 20120121723Abstract: An antimicrobial composition, including a synergistic combination of three or more agents as an active ingredient. Each of the three or more potentiating agents can be selected from the following types of compounds: sequestering agents, carbohydrates and carbohydrate derivatives, terpenes/terpenoids, amines and amine derivatives, plant-derived oils, sulfonates, phenols, fatty acids, dibenzofuran derivatives, organo isothiocyanates, quaternary ammonium compounds, peroxides and peroxide donors, and macrolide polyenes. At least two of the three or more potentiating agents are not of the same type of compound. The antimicrobial composition can have strong antimicrobial efficacy in control of microorganisms having resistance to currently used antimicrobials.Type: ApplicationFiled: January 25, 2012Publication date: May 17, 2012Applicant: Sterilex Technologies, LLCInventors: Pradip Mookerjee, Shira Kramer, Alexander Josowitz, April Zambelli-Weiner
-
Publication number: 20120121567Abstract: An ophthalmic solution containing riboflavin and at least a compound chosen in the group composed of essential and conditionally essential amino acids, coenzyme Q, L-proline, glycine, lysine hydrochloride, L-leucine, L-arginine and compounds intended to stimulate the production of metalloproteinase MMP9 for the protection of internal structures of the eyeball against UV-A rays or for the treatment of keratoconus with a trans-epithelial cross-linking technique.Type: ApplicationFiled: July 23, 2010Publication date: May 17, 2012Inventors: Salvatore Troisi, Antonio Del Prete, Ciro Caruso
-
Publication number: 20120121530Abstract: The present invention relates to certain DPP-4 inhibitors for treating and/or preventing oxidative stress, vascular stress and/or endothelial dysfunction as well as to the use of such DPP-4 inhibitors in treatment and/or prevention of diabetic or non-diabetic patients, including patient groups at risk of cardiovascular and/or renal disease.Type: ApplicationFiled: November 14, 2011Publication date: May 17, 2012Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBHInventors: Thomas KLEIN, Andreas DAIBER, Odd-Eric JOHANSEN, Michael MARK, Sanjaykumar PATEL, Hans-Juergen WOERLE
-
Publication number: 20120121727Abstract: The present application relates to novel substituted dihydropyrazolone derivatives, processes for their preparation, their use for treatment and/or prophylaxis of diseases and their use for the preparation of medicaments for treatment and/or prophylaxis of diseases, in particular cardiovascular and hematological diseases and kidney diseases, and for promoting wound healing.Type: ApplicationFiled: January 23, 2012Publication date: May 17, 2012Applicant: BAYER PHARMA AKTIENGESELLSCHAFTInventors: Kai THEDE, Ingo FLAMME, Felix OEHME, Jens-Kerim ERGÜDEN, Friederike STOLL, Joachim SCHUHMACHER, Hanno WILD, Peter KOLKHOF, Hartmut BECK, Jörg KELDENICH, Metin AKBABA, Mario JESKE